Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in preclinical models, including tumors that progressed after Enhertu treatment. The ongoing FOCUS-01 Phase 1 trial shows a favorable safety profile and pharmacokinetics consistent with preclinical predictions, with further efficacy data expected in the first half of 2027. This advancement could offer improved treatment options for patients with aggressive, resistant cancers.
Avacta Therapeutics data and trial design provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Oct 23, 2026 18:41 WIB: Of 150 priced health-sector US stocks, 31 rose and 112 fell. Dyne Therapeutics Inc. (DYN) traded at USD 15.52 with a 1-day change of -1.59% and 100% sell order activity. Cogent Biosciences Inc. (COGT) was priced at USD 30.85, down 1.47%. Novavax Inc (NVAX) closed at USD 9.85, down 1.40%, with 76% sell order activity and a typical hold time of 59 days on Pluang.
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
S&P Global Ratings has upgraded EssilorLuxottica's long-term credit rating to A+ with a stable outlook, recognizing the company's strong organic growth, solid cash flow, and robust balance sheet. The rating agency highlighted EssilorLuxottica's strat...
